Focus Laboratories Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Focus Laboratories Inc.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
- In Vitro Diagnostics
- Medical Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.